×
The central target of $13 is the arithmetic mean of four verified analyst price targets collected from Canaccord Genuity, Barrington Research, Stifel, and TD Cowen. At a recent price near $7.87 , reaching $13 would require roughly 65% upside , a very large move for a small-cap medical technology company.
OFIX dropped -15.12%, sliding from a previous close of $7.87 to $6.68, a decline that began in premarket trading and extended into the regular session. The selloff followed Q3 2026 results reported before the open: revenue of $207.9M missed estimates and the company cut full-year 2026 revenue guidance to $825M–$830M, well below the ~$851M consensus, citing U.S. spine softness and supplier delays.
DXCM is delivering double-digit revenue growth, expanding margins, and newly validated clinical data, while NVST is executing a steadier earnings recovery against persistent macro headwinds. The two companies operate in different corners of healthcare — DexCom in continuous glucose monitoring (CGM), and Envista in dental products and technologies — making this a study in contrasting growth profiles and risk exposures.
The central target of $100 is the arithmetic mean of 17 verified, current analyst price targets (roughly $99), rounded to a clean level. With the latest close near $79.41 , reaching $100 requires about a 26% gain — a substantial move from current levels.
Tickeron AI Verdict: Based on observable trend consistency, margin expansion, and catalyst breadth, Tickeron's AI currently favors DXCM in this head-to-head comparison. DXCM (DexCom) is a large-cap continuous glucose monitoring (CGM) leader delivering beat-and-raise results with expanding margins.
DXCM is delivering double-digit revenue growth and rising guidance, while ALGN is growing in the low single digits and recently trimmed its full-year revenue outlook. Both companies are profitable medical device leaders, but DXCM enjoys stronger near-term momentum, with shares up roughly 25% year to date versus a more mixed trajectory for ALGN .
Both DXCM and PODD operate in the diabetes technology market, but their recent trajectories have diverged sharply. DXCM delivered a beat-and-raise quarter, expanding margins and raising its 2026 outlook, while PODD beat on earnings but guided 2027 growth below its prior framework.
DXCM is riding stronger near-term momentum, with raised full-year guidance and positive clinical catalysts, while ISRG faces slowing U.S. procedure growth and a one-time litigation charge. Both are large-cap healthcare device leaders, but they serve different markets: diabetes management (DXCM) versus robotic-assisted surgery (ISRG).
DexCom, Inc. (DXCM) is a medical device company that designs and sells continuous glucose monitoring (CGM) systems for people with diabetes. The company was founded in 1999 and is headquartered in San Diego, California, trading on the Nasdaq since 2005.
Near-term commercial momentum: The full launch of the OneRF® Trigeminal Nerve Ablation System and continued adoption of the OneRF® Brain Ablation System are the clearest near-term revenue catalysts. Pipeline diversification: The StereoCED™ drug-delivery platform and the basivertebral nerve ablation (BVNA) program could expand NeuroOne beyond brain diagnostics into gene/cell therapy and chronic back-pain markets.
The $7.30 central target is the arithmetic mean of three verified analyst price targets ($5.00, $8.00, $8.80), rounded from $7.27. At a recent price near $0.88, reaching $7.30 implies roughly 730% upside — a very large move, not a modest re-rating.
Myomo is executing a strategic shift toward recurring referral-based patient acquisition, which reached 53% of revenue in the second quarter of 2026, roughly doubling from a year earlier. The next-generation MyoPro 3.0 device, featuring an AI-enabled processor, is advancing toward clinical validation in the first half of 2027, followed by manufacturing.
The central target of $4.75 is the arithmetic mean of five verified analyst price targets for Myomo, Inc. (MYO) , a wearable medical robotics company. Individual targets range widely from $1.70 (Craig-Hallum) to $11.00 (Ascendiant Capital), reflecting sharp disagreement about the company's trajectory.
Myomo (MYO) shares have declined roughly 16.6% over the trailing 30 days, falling from about $1.45 to $1.21 as a mid-August rally continued to unwind. The pullback extends a broader fade from the multi-month peak near $1.86 reached after strong second-quarter results in early August.
BSX has been pressured in recent weeks by a cybersecurity disruption, reduced full-year guidance, and share erosion in its electrophysiology (EP) and WATCHMAN franchises. JNJ recently raised its 2026 outlook, with pharmaceutical growth offsetting the loss of exclusivity (LOE) on Stelara, though its MedTech segment has decelerated.
Tickeron AI Verdict: MDT is the current favored ticker, reflecting stronger momentum, a steadier trend near its 52-week high, and fewer headline overhangs relative to ABT . ABT offers broad diversification across medical devices, diagnostics, nutrition, and pharmaceuticals, but recent performance has been weighed down by litigation costs and slowing growth in key product lines.
Kidney program is the defining catalyst: TransMedics is advancing its Organ Care System (OCS) for kidneys, targeting the largest transplant segment, with a U.S. Food and Drug Administration (FDA) clinical trial expected in early 2027 and a potential commercial launch in the second half of 2027. International expansion broadens the addressable market: The company is launching its National OCS Program (NOP) — its logistics and clinical-support network — in Europe, beginning with Italy, which management says could nearly double its total addressable market over time.
The central $100 target reflects the arithmetic mean of current analyst price targets, which recent aggregations place near $99, or roughly 13% above the latest verified price of $88.24. Following record third-quarter 2026 results, several firms raised targets: Canaccord Genuity to $120, Baird to $117, Needham to $110, JPMorgan to $85, and Stifel to $70, with the full range running approximately $70 to $125.
TransMedics delivered record third-quarter revenue of roughly $203 million, up 41% year over year and above consensus estimates. Adjusted earnings per share of $0.51 exceeded expectations, though GAAP net income declined as research, clinical, and interest expenses climbed.
Bluejay Diagnostics (NASDAQ: BJDX) is expected to report its third-quarter fiscal 2026 results around mid-November 2026. As a clinical-stage, pre-revenue medical diagnostics company, the report will center on net loss, cash burn, and balance sheet strength rather than revenue growth.
Previous
12 of 31
Next